1
|
Liu Y, Ruan X, Lei P, Shang B, Zhu Z, Chen S, Wang D, Wang R, Li X, Xue F. Acquired Hemophilia A: A Retrospective Multicenter Analysis of 42 Patients. Clin Appl Thromb Hemost 2023; 29:10760296221151165. [PMID: 36653966 PMCID: PMC9893059 DOI: 10.1177/10760296221151165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
INTRODUCTION Immunosuppressive therapy (IST) for acquired hemophilia A (AHA) results in remission within days to months in 60% to 80% of patients. However, little is known regarding the predictors of response. AIM This study aimed to identify the factors that influence response to treatment. METHODS The data of 42 patients with AHA from three hospitals were retrospectively analyzed. RESULTS All 42 AHA patients received IST; complete treatment data were available for 34 patients. The response rate was 60% among the 5/34 (14.7%) patients who received steroids alone, 70.8% among the 24/34 (70.6%) patients who received steroids plus cyclophosphamide, and 80% among the 5/34 (14.7%) patients who received steroids plus cyclophosphamide and rituximab. Overall, 29/34 (85.3%) patients achieved CR; 4/34 (13.8%) of them relapsed after a median time of 410 (21-1279) days. Adverse events occurred in 14/34 (41.2%) patients: 13/34 (38.2%) had infections and 1/34 (2.9%) developed pancytopenia. In univariate and multivariate Cox regression analyses, FVIII inhibitor titer ≥20 BU/mL was the only significant prognostic factor affecting time to CR. No variable had significant effect on OS. CONCLUSION FVIII inhibitory antibody titer ≥20 BU/mL appears to be an important predictor of time to complete response in patients with acquired hemophilia A treated with immunosuppressive therapy.
Collapse
Affiliation(s)
- Yanhui Liu
- Department of Hematology, Hemophilia Comprehensive Care Center, Henan Provincial People's Hospital, People's Hospital of Henan University, Zhengzhou, Henan Province, PR China,Yanhui Liu, Department of Hematology, Henan Provincial People's Hospital, 7 Weiwu Road, Jinshui District, Zhengzhou 450003, Henan, PR China.
Fei Xue, Department of Hepatobiliary and Pancreatic Surgery, Henan Provincial People's Hospital, 7 Weiwu Road, Jinshui District, Zhengzhou 450003, Henan, PR China.
| | - Xiang Ruan
- Department of Hematology, Hemophilia Comprehensive Care Center, Henan Provincial People's Hospital, People's Hospital of Henan University, Zhengzhou, Henan Province, PR China
| | - Pingchong Lei
- Department of Hematology, Hemophilia Comprehensive Care Center, Henan Provincial People's Hospital, People's Hospital of Henan University, Zhengzhou, Henan Province, PR China
| | - Baojun Shang
- Institute of Hematology, Hemophilia Comprehensive Care Center, Henan Provincial People's Hospital, People's Hospital of Henan University, Zhengzhou, Henan Province, PR China
| | - Zunmin Zhu
- Department of Hematology, Hemophilia Comprehensive Care Center, Henan Provincial People's Hospital, People's Hospital of Henan University, Zhengzhou, Henan Province, PR China,Institute of Hematology, Hemophilia Comprehensive Care Center, Henan Provincial People's Hospital, People's Hospital of Henan University, Zhengzhou, Henan Province, PR China
| | - Shengmei Chen
- Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, PR China
| | - Dao Wang
- Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, PR China
| | - Ruijuan Wang
- Department of Hematology, Nanyang Central Hospital, Nanyang, Henan Province, PR China
| | - Xiqing Li
- Department of Oncology, Henan Provincial People's Hospital, People's Hospital of Henan University, Zhengzhou, Henan Province, PR China
| | - Fei Xue
- Department of Hepatobiliary and Pancreatic Surgery, Henan Provincial People's Hospital, People's Hospital of Henan University, Zhengzhou, Henan Province, PR China
| |
Collapse
|
2
|
Mingot-Castellano ME, García Candel F, Benítez Hidalgo O, Marco A, Navarro GAM, Pérez-Montes R, Donas GG, Canaro M, Paloma MJ, Asenjo B, Calle-Gordo VM, González NP, González RR, Caparrón Miranda IS, París LQ, Herrero S, Nuñez R. Activated Prothrombin Complex Concentrate to Treat Bleeding Events in Acquired Hemophilia A: Bahas Study. Eur J Haematol 2022; 109:686-695. [PMID: 36029160 DOI: 10.1111/ejh.13853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2022] [Revised: 08/19/2022] [Accepted: 08/22/2022] [Indexed: 11/26/2022]
Abstract
OBJECTIVE Activated prothrombin complex concentrate (aPCC) is a bypassing agent indicated to treat bleeds in patients with acquired hemophilia A (AHA). Nevertheless, its efficacy and safety in the real-world setting has not often been addressed. METHODS We report the experience of Spanish reference centers for coagulation disorders and from acquired haemophilia Spanish Registry (AHASR), from August 2012 to February 2021. Follow-up period of 30 days after aPCC withdrawal. RESULTS Thirty patients with a median age of 70 years old, suffering from 51 bleeds treated with aPCC were finally evaluated. As first line treatment, aPCC stopped bleed in 13 of 14 (92.9%) cases. aPCC as second line after recombinant factor VIIa failure, stopped bleeding in the all cases. In 17 patients aPCC was used far from initial bleed control as prophylaxis of rebleeding with 94% effectiveness. No thromboembolic episodes was communicated. One patient developed hypofibrinogenemia, which did not prevent aPCC from halting bleeding. No other serious adverse events possibly or probably associated with aPCC were reported. CONCLUSIONS this data support aPCC as haemostatic treatment in AHA with high effectiveness and excellent safety profile in acute bleeds and as extended use to prevent rebleedings, even in anging people with high cardiovascular risk. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- María Eva Mingot-Castellano
- Hematology Department, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.,Hematology Department, Hospital Regional Universitario de Málaga, Málaga, Spain
| | | | | | - Ana Marco
- Hematology Department, Hospital General de Alicante4, Alicante, Spain
| | | | | | - Gloria García Donas
- Hematology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - Mariana Canaro
- Hematology Department, Hospital Son Espases, Palma de Mallorca, Spain
| | - María José Paloma
- Hematology Department, Hospital Universitario Virgen del Camino, Pamplona, Spain
| | - Beatríz Asenjo
- Hematology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | | | | | | | | | - Laura Quintana París
- Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
| | - Sonia Herrero
- Hematology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain
| | - Ramiro Nuñez
- Hematology Department, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain
| |
Collapse
|
3
|
Diagnosis and Management of Acquired Hemophilia A: Case Reports and a Literature Review. Case Rep Med 2021; 2021:5554664. [PMID: 34567128 PMCID: PMC8457949 DOI: 10.1155/2021/5554664] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 07/20/2021] [Accepted: 08/26/2021] [Indexed: 11/17/2022] Open
Abstract
Background Acquired hemophilia A (AHA) is a potentially life-threatening autoimmune hemostatic disorder where autoantibodies that disrupt the functions of factor VIII (FVIII) are present in the circulation. The early diagnosis of AHA is difficult since the symptoms of AHA differ from those of congenital hemophilia A. Furthermore, the management of AHA is also more complex due to the presence of autoantibodies against FVIII (FVIII inhibitors). Here, we present three case reports and conduct a literature review of AHA with the aim to increase awareness and knowledge regarding the diagnosis and treatment of AHA. Case Presentations. We present three patients diagnosed with AHA in these case reports. The first patient was a young female, while the second and third patients were middle-aged and elderly males, respectively. All patients presented with a chief complaint of bruises without hemarthrosis and a history of bleeding. Laboratory examinations of the patients revealed isolated prolonged aPTT, normal PT, and the presence of autoantibodies against factor VIII, which are characteristics of AHA. Patients were then treated with corticosteroids to reduce the titer level of autoantibodies and received factor VIII transfusion to stop bleeding. Conclusion AHA can be suspected in patients presenting with symptoms of bruises without hemarthrosis and without the history of bleeding. Isolated aPTT elevation with normal PT should raise high suspicion of AHA. The presence of FVIII inhibitors can help to confirm the diagnosis of AHA. Treatment consists of factor VIII transfusion and corticosteroid therapy. Bypassing agents are recommended as an alternative to FVIII transfusion.
Collapse
|
4
|
Szczepanik A, Pielaciński K, Oses-Szczepanik A, Paluszkiewicz P. Gastric ulcer bleeding in acquired hemophilia A patient and persistent inhibitor successfully treated with endoscopic methods of hemostasis. POLISH JOURNAL OF SURGERY 2021. [DOI: 10.5604/01.3001.0014.8451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACT: Acquired hemophilia A (AHA) is extremely rare, life-threatening bleeding disorder caused by sudden development of autoantibodies against coagulation factor VIII. Invasive procedures in AHA patients with persistent inhibitor, resistant to eradication therapies, pose an extreme threat of life due to uncontrolled bleeding poorly respond to surgical methods of hemostasis and bypassing agents. We report a case of idiopathic AHA 71-year-old patient with persistent high-titer inhibitor (104 BU) resistant to immunosuppressive treatment and immune tolerance induction. The patient was admitted with severe bleeding gastric ulcer complicated by gastric mucosal lacerations (Mallory-Weiss tears). Repeated endoscopic treatment with injection therapy and argon plasma coagulation were applied resulting in bleeding arrest. As bypassing agent recombinant active factor VII (rFVIIa) was applied with an average dose of 91.26 µg/kg (administering cumulatively of 134 doses during 14 days) and the total dose of 855.82 mg. In conclusion, gastric ulcer bleeding in AHA patient with persistent inhibitor can be successfully arrested with the use of endoscopic hemostasis methods and proper doses of rFVIIa.
Collapse
Affiliation(s)
- Andrzej Szczepanik
- Department of General, Oncological and Metabolic Surgery, Institute of Hematology and Transfusion Medicine in Warsaw
| | - Konrad Pielaciński
- Instytut Hematologii i Transfuzjologii w Warszawie Klinika Chirurgii Ogólnej, Onkologicznej i Metabolicznej
| | - Anna Oses-Szczepanik
- Uniwersytet Jagielloński w Krakowie Collegium Medicum Klinika Chorób Wewnętrznych i Geriatrii
| | - Piotr Paluszkiewicz
- Department of General, Oncological and Metabolic Surgery, Institute of Hematology and Transfusion Medicine in Warsaw
| |
Collapse
|
5
|
Acquired Haemophilia A: An Intriguing Disease. Mediterr J Hematol Infect Dis 2020; 12:e2020045. [PMID: 32670523 PMCID: PMC7340240 DOI: 10.4084/mjhid.2020.045] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Accepted: 06/18/2020] [Indexed: 12/31/2022] Open
Abstract
Abstract. Acquired Haemophilia A is a rare acquired bleeding disorder caused by Factor VIII autoantibodies, which neutralise FVIII activity. These inhibitors differ from alloantibodies against FVIII, which can occur in congenital Haemophilia A after repeated exposures to plasma-derived or recombinant FVIII products. In most cases, the disease occurs suddenly in subjects without a personal or familiar history of bleedings, with symptoms that may be mild, moderate, or severe. However, only laboratory alterations are present in ~ 30% of patients. The incidence varies from 1 to 4 cases per million/year; more than 80% of patients are elderly, males and females are similarly affected. There is a small peak of incidence related to pregnancy in young women aged 20–40 years. The disease may be underdiagnosed in the elderly. The diagnostic algorithm is based on an isolated prolonged activated partial thromboplastin time, normal thrombin time, absence of Lupus Anticoagulant, and a mixing test that reveals the presence of an inhibitor: the finding of reduced FVIII activity and the detection of neutralising autoantibodies against FVIII lead to the diagnosis. The disease is idiopathic in 44%–63% of cases, while in the others etiological factors are present. Bleeding prevention and treatment are based on therapeutic tools as by-passing agents, recombinant porcine FVIII concentrate or, in a limited number of cases, FVIII concentrates and desmopressin. As soon as the diagnosis has been made, immunosuppressive therapy must be started to eradicate the inhibitor. Better knowledge of the disease, optimal management of bleeding and eradication of the inhibitor have significantly reduced morbidity and mortality in most patients.
Collapse
|
6
|
Susoctocog-alfa (Obizur ®) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real world experience. BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE 2020; 18:312-321. [PMID: 32698943 DOI: 10.2450/2020.00006-20] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Accepted: 03/19/2020] [Indexed: 01/29/2023]
Abstract
BACKGROUND In 2016, a new recombinant B-domain deleted porcine FVIII (rpFVIII) was licensed in Italy for the treatment of acquired haemophilia A (AHA), but only a few cases of patients receiving this have been reported in the literature. Here we report the largest registry of the use of rpFVIII for the treatment of AHA. The objective of this retrospective study was to describe the efficacy and the safety of susoctocog-alfa for AHA. MATERIAL AND METHODS We studied a population of nine patients, recruited in five Italian haemophilia centres presenting AHA, and treated with Obizur® as first- or second-line therapy. RESULTS rpFVIII was used as a first-line therapy in one-third of the patients. The median delay between clinical onset and diagnosis was 16 days. Initial bolus of infused susoctocog-alfa was 100 IU/kg, lower than the recommended dose. The treatment was maintained for a median of four days. Only one patient with serious co-morbidities and recurrent infections was treated for 32 days. All patients reached a complete resolution of AHA, and no recurrences were reported. Two patients developed a low-titre inhibitor against rpFVIII, neither experienced any complications. DISCUSSION In our real world experience, susoctocog-alfa was proven to be an effective and safe therapeutic option for patients with AHA, also at a lower than recommended dosage. In our report, the appearance of low-titre inhibitors against rpFVIII, was not found to be clinically significant.
Collapse
|
7
|
Kim CH, Simmons SC, Wang D, Najafzadeh P, Azad A, Pham HP. An economic analysis of different treatments for bleeding in patients with acquired haemophilia. Vox Sang 2019; 115:192-199. [PMID: 31879973 DOI: 10.1111/vox.12877] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Revised: 11/07/2019] [Accepted: 11/30/2019] [Indexed: 01/19/2023]
Abstract
BACKGROUND Acquired haemophilia A (AHA), with potentially high risk of morbidity and mortality, occurs as a result of inhibitors against factor VIII. Bleeding due to AHA can be treated with activated prothrombin complex concentrate (aPCC), recombinant activated factor VII (rFVIIa) or recently, recombinant porcine-sequence factor VIII (rpFVIII). We extended our previous cost-effectiveness analysis (CEA) comparing rpFVIII against the available traditional options. METHODS For high-titred, haemorrhaging AHA patients treated with either aPCC, rFVIIa or rpFVIII, over the course of 6-days, a Markov simulation was conducted to evaluate the outcomes when these patients transitioned into any of the four following health states: (1) continuous bleeding, (2) thrombosis, (3) stop bleeding and (4) death, with states (2), (3) and (4) modelled as absorbing states. All model parameters were obtained from the medical literature, except the costs of aPCC, rFVIIa and the factor VIII assay, which came from our institutional data. RESULTS Excluding the cost of the initial treatment on day 0, the total subsequent treatment cost of rFVIIa was substantially more than the costs of aPCC and rpFVIII ($13 925 vs. $1778 vs. $6957, respectively). The average quality-adjusted life days (QALDs) gained from rpFVIII was lowest (4·89 vs. 4·9 for rFVIIa and 4·91 for aPCC). Overall, aPCC dominated the other two treatments. The model was determined to be robust across the tested ranges for all input variables. CONCLUSION Based on this economic model, for AHA patients with high titres who were bleeding, aPCC was the most cost-effective treatment option and may be considered for use if there is no clinical contraindication.
Collapse
Affiliation(s)
- Chong H Kim
- Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - Sierra C Simmons
- Department of Pathology, Michigan Pathology Specialists and Spectrum Health Hospitals, Grand Rapids, MI, USA
| | - Dandan Wang
- Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Parisa Najafzadeh
- Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Ameneh Azad
- Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Huy P Pham
- Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| |
Collapse
|
8
|
Pandey Y, Atwal D, Konda M, Roy A, Sasapu A. Acquired hemophilia A. Proc (Bayl Univ Med Cent) 2019; 33:71-74. [PMID: 32063777 DOI: 10.1080/08998280.2019.1689024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Revised: 10/25/2019] [Accepted: 10/31/2019] [Indexed: 10/25/2022] Open
Abstract
Acquired inhibitors of coagulation are a group of rare but potentially life-threatening blood disorders characterized by the presence of autoantibodies directed against clotting factor. Autoantibody against factor VIII is the most common form of clotting factor inhibitor, a condition also known as acquired hemophilia A. We present a clinical series of nine patients diagnosed and treated for acquired hemophilia A at our institution. Among these nine patients, there were five men and four women with a median age of 64 years. All patients presented with bleeding diathesis. Factor eight inhibitor bypassing agent and/or recombinant factor VIIa were predominantly used for control of active bleeding. For elimination of autoantibodies, either steroids alone or the combination of steroids with rituximab or oral cyclophosphamide was used. Despite aggressive measures, two of the patients had a poor outcome; seven of the nine patients (77%) had a good clinical outcome. Acquired hemophilia A should be strongly suspected in any patient presenting with bleeding and a prolonged activated partial thromboplastin time. Early initiation of factor bypassing agents such as activated prothrombin complex concentrates or recombinant factor VIIa, along with the use of immunosuppressive agents, can be lifesaving.
Collapse
Affiliation(s)
- Yadav Pandey
- Department of Internal Medicine, University of Arkansas for Medical SciencesLittle RockArkansas
| | - Dinesh Atwal
- Department of Hematology and Oncology, University of Arkansas for Medical SciencesLittle RockArkansas
| | - Manojna Konda
- Department of Internal Medicine, University of Arkansas for Medical SciencesLittle RockArkansas
| | - Arya Roy
- Department of Internal Medicine, University of Arkansas for Medical SciencesLittle RockArkansas
| | - Appalanaidu Sasapu
- Department of Hematology and Oncology, University of Arkansas for Medical SciencesLittle RockArkansas
| |
Collapse
|
9
|
Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII. Case Rep Hematol 2019; 2019:9026121. [PMID: 31559096 PMCID: PMC6735189 DOI: 10.1155/2019/9026121] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2019] [Accepted: 08/08/2019] [Indexed: 12/05/2022] Open
Abstract
Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies against Factor VIII (FVIII). It has a high mortality due to bleeding complications. FVIIa-based bypassing agents are the first line of treatment but not always effective. Recombinant porcine (rp) FVIII (Obizur®) was recently approved for rescue treatment but with little evidence-based information regarding efficacy. We report a case of papillary thyroid cancer associated with AHA malignancy that responded to a single dose of rpFVIII after failure to achieve hemostasis with FVIIa-based bypassing products.
Collapse
|
10
|
Yamada S, Arahata M, Morishita E, Ichinose A, Asakura H. The first reported case of acquired haemophilia A in which bleeding episodes were successfully treated via administration of a single-dose mixture of activated factor VIIa/X. Haemophilia 2019; 25:e350-e352. [PMID: 31487088 DOI: 10.1111/hae.13843] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Revised: 08/06/2019] [Accepted: 08/06/2019] [Indexed: 11/27/2022]
Affiliation(s)
- Shinya Yamada
- Department of Hematology, Kanazawa University Hospital, Ishikawa, Japan
| | - Masahisa Arahata
- Department of Hematology, Kanazawa University Hospital, Ishikawa, Japan
| | - Eriko Morishita
- Department of Hematology, Kanazawa University Hospital, Ishikawa, Japan
| | - Akitada Ichinose
- Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School, Yamagata, Japan
| | - Hidesaku Asakura
- Department of Hematology, Kanazawa University Hospital, Ishikawa, Japan
| |
Collapse
|
11
|
Sun B, Xue F, Feng Y, Sun J, Yu Z, Hou M, Zhang J, Zeng X, Zhao Y, Lian S, Huang M, Niu T, Cui Z, Wu J, Yang R. Outcome of CARE: a 6‐year national registry of acquired haemophilia A in China. Br J Haematol 2019; 187:653-665. [PMID: 31372978 DOI: 10.1111/bjh.16128] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 05/27/2019] [Indexed: 02/05/2023]
Affiliation(s)
- Boyang Sun
- State Key Laboratory of Experimental Haematology, National Clinical Research Centre for Haematological Disorders Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases TianjinChina
| | - Feng Xue
- State Key Laboratory of Experimental Haematology, National Clinical Research Centre for Haematological Disorders Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases TianjinChina
| | - Ying Feng
- Department of Haematology Second Affiliated Hospital of Guangzhou Medical University GuangzhouChina
| | - Jing Sun
- Nanfang Hospital Nanfang Medical University GuangzhouChina
| | - Ziqiang Yu
- Department of Haematology The First Affiliated Hospital of Soochow University SuzhouChina
| | - Ming Hou
- Department of Haematology Qilu Hospital, Shandong University Jinan ShandongChina
| | - Jingyu Zhang
- Department of Haematology, Key Laboratory of Haematology of Hebei Province The Second Hospital of Hebei Medical University Shijiazhuang HebeiChina
| | - Xiaojing Zeng
- Department of Blood Transfusion The Affiliated Hospital of Guizhou University GuiyangChina
| | - Yongqiang Zhao
- Department of Haematology Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences BeijingChina
| | - Shimei Lian
- Department of Haematology Dalian Municipal Central Hospital, Affiliated Hospital of Dalian Medical University Dalian China
| | - Meijuan Huang
- Fujian Institute of Haematology Fujian Medical University Union Hospital FuzhouChina
| | - Ting Niu
- Department of Haematology West China Hospital, Sichuan University Chengdu SichuanChina
| | - Zhongguang Cui
- The Affiliated Hospital of Qingdao University QingdaoChina
| | - Jingsheng Wu
- Department of Haematology Anhui Provincial Hospital, Anhui Medical University Hefei China
| | - Renchi Yang
- State Key Laboratory of Experimental Haematology, National Clinical Research Centre for Haematological Disorders Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases TianjinChina
| |
Collapse
|
12
|
Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry. Thromb Res 2019; 174:24-26. [DOI: 10.1016/j.thromres.2018.12.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Revised: 11/15/2018] [Accepted: 12/05/2018] [Indexed: 11/20/2022]
|
13
|
Management of Acquired Hemophilia A in Elderly Patients. Case Rep Hematol 2018; 2018:6757345. [PMID: 30538871 PMCID: PMC6260550 DOI: 10.1155/2018/6757345] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Revised: 10/07/2018] [Accepted: 10/11/2018] [Indexed: 11/17/2022] Open
Abstract
This report describes six elderly patients with acquired hemophilia A (AHA), including four individuals aged ≥90 years. Bleeding symptoms were subcutaneous or intramuscular hemorrhage (n=4), hematuria (n=1), and hemorrhagic shock after tooth extraction (n=1). Factor VIII (FVIII) activity ranged from <1.0% to 3.0%, and anti-FVIII inhibitor titers ranged from 8.8 to 240 BU/mL. Treatment was administered at the discretion of the responsible physician. Hemostatic agents applied in the six patients comprised rFVIIa (NovoSeven®) (n=4), APCC (Feiba®) (n=2), and fresh frozen plasma/plasma exchange (n=1). Agents employed for inhibitor eradication comprised prednisolone only (n=3), prednisolone with cyclophosphamide (n=1), prednisolone with cyclosporine (n=1), and prednisolone with rituximab (n=1). In five patients, management was successful, with complete response. Treatment failed in the patient with the highest inhibitor level (240 BU/mL) in whom treatment with APCC (Feiba®; 100 U/kg/dose, three doses) and prednisolone (0.5 mg/kg/day) was followed by several episodes of relapse. The present data demonstrate that AHA severity shows wide variation in elderly subjects, indicating the necessity of individualized management.
Collapse
|
14
|
Kim CH, Simmons SC, Bui CM, Jiang N, Pham HP. aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model. Vox Sang 2018; 114:63-72. [DOI: 10.1111/vox.12726] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Revised: 10/23/2018] [Accepted: 10/29/2018] [Indexed: 01/27/2023]
Affiliation(s)
- Chong H. Kim
- Department of Clinical Pharmacy; University of Colorado Anschutz Medical Campus; Aurora CO USA
| | | | | | - Ning Jiang
- Center for Family Life at Sunset Park; SCO Family of Services; Brooklyn NY USA
| | - Huy P. Pham
- Department of Pathology; Keck School of Medicine; University of Southern California; Los Angeles CA USA
| |
Collapse
|
15
|
Charlebois J, Rivard GÉ, St-Louis J. Management of acquired hemophilia A: Review of current evidence. Transfus Apher Sci 2018; 57:717-720. [PMID: 30396835 DOI: 10.1016/j.transci.2018.10.011] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Acquired hemophilia A (AHA) is a rare acquired bleeding disorder caused by autoantibodies against autologous factor VIII (FVIII). It is a disease that most commonly affects the elderly, but it has been described in children and during the post-partum period. It is idiopathic in 50% of cases and is associated with autoimmune disease, malignancy, pregnancy, infection or certain medications in the other 50%. The diagnosis should be suspected in patients with an isolated prolonged aPPT without previous personal or familial bleeding history. Treating the bleeding and eradication of the inhibitor is the mainstay of treatment. The first line of treatment for acute bleeding is the use of bypassing agents. The most commonly used method for eradicating the inhibitor is immunosuppression, namely corticosteroids alone or in combination with cyclophosphamide. This review summarises current knowledge and reviews management options and guidelines.
Collapse
Affiliation(s)
- Janie Charlebois
- Division of Hematology/Oncology, Centre Hospitalier Universitaire Sainte-Justine, Department of Pediatrics, Université de Montréal, Montréal, Qc, Canada
| | - Georges-Étienne Rivard
- Division of Hematology/Oncology, Centre Hospitalier Universitaire Sainte-Justine, Department of Pediatrics, Université de Montréal, Montréal, Qc, Canada
| | - Jean St-Louis
- Division of Hematology/Oncology, Hôpital Maisonneuve-Rosemont, Department of Medicine, Université de Montréal, Montréal, Qc, Canada.
| |
Collapse
|
16
|
[Chinese guidelines on the diagnosis and treatment of coagulation factor Ⅷ/Ⅸ inhibitors (version 2018)]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2018; 39:793-799. [PMID: 30369197 PMCID: PMC7348289 DOI: 10.3760/cma.j.issn.0253-2727.2018.10.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Indexed: 12/15/2022]
|
17
|
Pasca S, Ambaglio C, Rocino A, Santoro C, Cantori I, Zanon E. Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry. J Thromb Thrombolysis 2018; 47:129-133. [PMID: 30267246 DOI: 10.1007/s11239-018-1750-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and improves the efficacy of therapy, but can increase the risk of severe side effects. Due to these premises it has always raised doubts and perplexities in the clinics. We now report the data of the "FEIBA® on acquired haemophilia A Italian Registry (FAIR Registry)", a retrospective-prospective study that included 56 patients. This is the first study that assessed the clinical response of the combination of aPCC and antifibrinolytic agents in patients with acquired haemophilia A. A total of 101 acute bleeds were treated with aPCC. Antifibrinolytic agents were used in the treatment of 39.6% of total bleeds, based on both, a clinical assessment and an evaluation of bleeding. Twenty-five of the 30 patients (57.1%) treated with antifibrinolytic drugs showed serious co-morbidity. Among them, 40% presented severe cardiovascular diseases. All bleeds treated with combined therapy had a shorter duration of treatment (mean reduction 16.3%). All the treated patients presented a good tolerability and no arterial or venous thromboembolic events were reported. In our retrospective registry the combination of antifibrinolytics and aPCC appears safe and effective in the treatment of patients with AHA, especially in the case of severe and life-threatening bleeding, but this hypothesis needs to be confirmed in adequate, larger clinical trials.
Collapse
Affiliation(s)
- S Pasca
- Haemophilia Centre, University Hospital of Padua, Via Giustiniani, 35128, Padua, Italy.
| | - C Ambaglio
- Haemophilia Centre, S.Matteo Hospital of Pavia, Pavia, Italy
| | - A Rocino
- Haemophilia and Thrombosis Centre, S.Giovanni Bosco Hospital of Neaples, Naples, Italy
| | - C Santoro
- Cellular Biotecnology and Haematology Department, Umberto I University Hospital of Rome, Rome, Italy
| | - I Cantori
- Centre of Coagulation Diseases, Hospital of Macerata, Macerata, Italy
| | - E Zanon
- Haemophilia Centre, University Hospital of Padua, Via Giustiniani, 35128, Padua, Italy
| | | |
Collapse
|
18
|
A decade-long clinical experience on the prophylactic use of activated prothrombin complex concentrate in acquired haemophilia A: a case series from a tertiary care centre. Blood Coagul Fibrinolysis 2018; 29:282-287. [PMID: 29474202 DOI: 10.1097/mbc.0000000000000716] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
: In acquired haemophilia A (AHA), risk for recurrent bleeding exists until the inhibitor is detectable. Thus, patients with persisting inhibitor may benefit from prophylaxis with activated prothrombin complex concentrate (aPCC). Potential thromboembolic complications and cost are also factors to consider. Today, no high level evidence or clear recommendations are available on aPCC prophylaxis in AHA. Recently, a small prospective study demonstrated a favourable outcome with short-term, daily administered aPCC infusion. Here we report a retrospective case series of 19 patients with AHA to demonstrate our practice on aPCC prophylaxis. In our practice, clinical bleeding tendency guided our decision on the initiation of aPCC prophylaxis. In patients with serious bleeding tendency, aPCC infusion was prolonged beyond bleeding resolution in a twice-weekly or thrice-weekly regimen. Serious bleeding phenotype included a single episode of life-threatening bleeding or recurrent, severe haemorrhages. Patients who did not present such events were treated on-demand. The preventive dose of aPCC was equal with the lowest effective therapeutic dose. Prophylaxis was continued until the inhibitor disappeared. Eleven patients received aPCC prophylaxis. In nine cases, prophylaxis lasted beyond two months. No severe bleeding developed spontaneously and no thromboembolic complication occurred in the median 16 weeks (interquartile range 9-34) duration of prophylaxis. Eight patients of the nonprophylaxis group did not present any severe haemorrhage. According to our experience, we consider prophylaxis with aPCC effective and well tolerated for patients with AHA and serious bleeding tendency, until the acquired inhibitor persists.
Collapse
|
19
|
Casadiego-Peña C, González-Motta A, Perilla OG, Gomez PD, Enciso LJ. Acquired Hemophilia Secondary to Soft-tissue Sarcoma: Case Report from a Latin American Hospital and Literature Review. Cureus 2018; 10:e2621. [PMID: 30027013 PMCID: PMC6044478 DOI: 10.7759/cureus.2621] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Acquired hemophilia A is a rare bleeding disorder caused by inhibiting antibodies against factor VIII characterized by the presence of severe bleeding, which in occasions can be lethal. The bleeding manifestations typically have a sudden onset and patients have a negative family and personal histories of bleeding, with a normal prothrombin time (PT) and an extended partial thromboplastin time (PTT). Incidence has been calculated to be between 0.2 and 1.48 cases per million per year. Between 6% and 15% of cases are associated with neoplasms. Here, we present a 52-year-old male with back myxofibrosarcoma who developed acquired hemophilia without response to treatment used and ultimately died. The most common cancers associated with acquired hemophilia are lung and prostate cancer. We found one other case of a patient with Kaposi's sarcoma that was unassociated with HIV infection who presented with severe postoperative bleeding. For bleeding in acquired hemophilia A, the treatments of choice are "bypass" agents, such as recombinant-activated factor VIII (rFVIIa) or activated prothrombin complex concentrate. Any delay in the start of treatment or the usage of insufficient doses is associated with the progression of bleeding symptoms and worsening general condition. In the case of acquired hemophilia secondary to neoplasia, it is recommended that immunosuppressive therapy to eradicate the inhibitors be combined with treatment for the underlying neoplastic disease. In our patient, it was not possible to offer a surgical treatment that enabled the control of the neoplasia, nor he was considered a candidate for chemotherapy or radiotherapy, limiting the treatment to immunosuppressive and "bypass" management.
Collapse
Affiliation(s)
- Camila Casadiego-Peña
- Department of Radiation Oncology, Instituto Nacional de Cancerologia, Universidad Militar Nueva Granada, Bogota, COL
| | - Alejandro González-Motta
- Department of Radiation Oncology, Instituto Nacional de Cancerologia, Universidad Militar Nueva Granada, Bogota, COL
| | - Oliver G Perilla
- Department of Hematology, Instituto Nacional De Cancerologia, Bogota, COL
| | - Pedro D Gomez
- Faculty of Medicine, Universidad Nacional De Colombia, Bogota, COL
| | - Leonardo J Enciso
- Department of Internal Medicine, Instituto Nacional De Cancerologia, Bogota, COL
| |
Collapse
|
20
|
Can the plasmaderived factor VIII still play a role in the treatment of acquired hemophilia A at the time of new drugs? Blood Coagul Fibrinolysis 2018; 29:417-422. [PMID: 29608457 DOI: 10.1097/mbc.0000000000000734] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
: Bypassing agents are the first-line therapy in the treatment of acquired hemophilia A (AHA), but not the only one. Other options as recombinant porcine factor VIII or plasmaderived concentrates (pdFVIII) are available to clinicians. Aim of this study was to evaluate whether the pdFVIII can still play a role in the treatment of AHA, and which patients could benefit from this therapy. All patients with AHA, presenting severe cardiovascular comorbidities, and treated with pdFVIII with or without von Willebrand factor (vWF), referred to two different hospitals, were initially considered. Eight patients were studied and divided into two groups: first, patients treated with daily infusion of pdFVIII; second, patients treated with pdFVIII continuous infusion. After 6 months of follow-up, all patients reached complete response. Mean consumption of clotting factor (219 000 vs. 142 000 IU), mean duration of therapy (61.5 vs. 10.5 days), and mean time necessary to disappearance of the inhibitors (INHs) (64 vs. 9 days) were higher in group 1, and the differences between the two groups were statistically significant (P < 0.05). Patients in group 1 also had a mean INH titer of 20.4 BU, higher than that of group 2 patients (8.4 BU), with a lower detectable FVIII level. Our study showed that pdFVIII can be an effective option for patients at high thromboembolic risk, even for those with high-titer INHs, especially if combined with vWF. The immunomodulatory role of vWF should, however, be better investigated in wider trials. The days of treatment with pdFVIII continuous infusion was proven to be similar to those reported with other drugs.
Collapse
|
21
|
Zanon E, Pasca S, Santoro C, Gamba G, Siragusa SM, Rocino A, Cantori I, Federici AB, Mameli L, Giuffrida G, Falanga A, Lodigiani C, Santoro RC, Milan M, Ambaglio C, Napolitano M, Mazzucconi MG. Activated prothrombin complex concentrate (FEIBA®
) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry. Br J Haematol 2018. [DOI: 10.1111/bjh.15175] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Ezio Zanon
- Haemophilia Centre; University Hospital of Padua; Padova Italy
| | - Samantha Pasca
- Haemophilia Centre; University Hospital of Padua; Padova Italy
| | - Cristina Santoro
- Cellular Biotechnology and Haematology Department; Umberto I University Hospital; Roma Italy
| | | | - Sergio M. Siragusa
- Centre of Haemorrhagic and Thrombotic Diseases; University of Palermo; Palermo Italy
| | - Angiola Rocino
- Haemophilia and Thrombosis Centre; S. Giovanni Bosco Hospital; Napoli Italy
| | - Isabella Cantori
- Centre of Coagulation Diseases; Hospital of Macerata; Macerata Italy
| | - Augusto B. Federici
- Haematology and Transfusion Medicine Department; Luigi Sacco Hospital; Milano Italy
| | - Luciana Mameli
- Center of Coagulation Diseases; SS Annunziata Hospital; Sassari Italy
| | - Gaetano Giuffrida
- Haematology Department; VE Ferrarotto and S. Bambino University Hospital; Catania Italy
| | - Anna Falanga
- Transfusion Medicine and Immune-haematology Department; Giovanni XXIII Hospital; Bergamo Italy
| | - Corrado Lodigiani
- Medicine Department; Humanitas Clinical Institute; Rozzano (Milano) Italy
| | - Rita C. Santoro
- Centre of Haemorrhagic and Thrombotic Diseases; Pugliese-Ciaccio Hospital; Catanzaro Italy
| | - Marta Milan
- Haemophilia Centre; University Hospital of Padua; Padova Italy
| | | | - Mariasanta Napolitano
- Centre of Haemorrhagic and Thrombotic Diseases; University of Palermo; Palermo Italy
| | - Maria G. Mazzucconi
- Cellular Biotechnology and Haematology Department; Umberto I University Hospital; Roma Italy
| |
Collapse
|
22
|
Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. Blood Adv 2017; 1:2637-2642. [PMID: 29296916 DOI: 10.1182/bloodadvances.2017011536] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Accepted: 11/09/2017] [Indexed: 11/20/2022] Open
Abstract
Anti-inhibitor coagulant complex (AICC), an activated prothrombin complex concentrate, has been available for the treatment of patients with inhibitors since 1977, and thromboembolic events (TEEs) have been reported after infusion of AICC in patients with congenital or acquired hemophilia. With the aim of estimating the TEE incidence rate (IR) related to AICC exposure in these patients, a systematic review of the literature was carried out in Medline, according to PRISMA guidelines, from inception date to March 2017. The IR of TEEs was estimated through a meta-analytic approach by using a generalized linear mixed model based on a Poisson distribution. Thirty-nine studies were included (1980-2016). Overall, 46 TEEs were reported; of these, 13 were reported as disseminated intravascular coagulations, 11 as myocardial infarctions, and 3 as thrombotic cerebrovascular accidents. The pooled TEE IR was 2.87 (95% confidence interval [CI], 0.32-25.40) per 100 000 AICC infusions (5.42 in retrospective studies [95% CI, 0.92-31.82]; 1.09 in prospective studies [95% CI, 0.01-238.77]). The TEE rate was 5.09 (95% CI, 0.01-1795.60) per 100 000 AICC infusions administered on demand, whereas no TEEs were reported with prophylaxis. Interestingly, the estimated IR in patients with congenital hemophilia was <0.01 per 100 000 infusions. These findings provide robust evidence of safety of AICC over almost 40 years of published studies.
Collapse
|
23
|
Napolitano M, Siragusa S, Mancuso S, Kessler CM. Acquired haemophilia in cancer: A systematic and critical literature review. Haemophilia 2017; 24:43-56. [PMID: 28960809 DOI: 10.1111/hae.13355] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/01/2017] [Indexed: 12/12/2022]
Abstract
AIM There is a paucity of data on the clinical presentation and management of cancer patients with acquired haemophilia (AH), we here report a systematic literature review on acquired haemophilia in the context of cancer. METHODS Treatment outcomes of AH were defined as complete response (CR), partial response (PR) or no response (NR), based on inhibitor eradication, coagulation factor VIII levels and bleeding control. Reported deaths were either related to cancer or bleeding. RESULTS Overall, 105 cases were collected and analyzed according to classification of cancer and efficacy of treatments for inhibitor and malignancy. The mean age was 68 years for both males (range 37-86 years) and females (range 43-89 years), 39 patients were female subjects and 66 were males. A solid cancer was diagnosed in 60 subjects, while 45 patients suffered a haematological malignancy. Solid cancers affected mainly males; however, the incidence of solid tumours vs haematological malignancies was not statistically significant (P = .09). Not all patients were treated for their underlying cancer, bleeding and/or inhibitor, in two cases outcome is unavailable. CR was reported in 62.1% (64/103) cases, PR in 9.7% (10/103) cases, NR with or without death was reported in 28.1% (29/103) cases. CONCLUSION CR was best achieved when successful and complete elimination of autoantibodies occurred contemporaneously with the successful treatment of the underlying malignancy. In some cases, recurrent autoantibodies were harbingers of relapsed cancer. Type of cancer, inhibitor titer, treatments administered for bleeding control and inhibitor eradication did not significantly affect clinical outcome of analyzed cases.
Collapse
Affiliation(s)
- M Napolitano
- Hematology Unit, Thrombosis and Hemostasis Reference Regional Center, Università degli studi di Palermo, Palermo, Italy
| | - S Siragusa
- Hematology Unit, Thrombosis and Hemostasis Reference Regional Center, Università degli studi di Palermo, Palermo, Italy
| | - S Mancuso
- Hematology Unit, Thrombosis and Hemostasis Reference Regional Center, Università degli studi di Palermo, Palermo, Italy
| | - C M Kessler
- Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| |
Collapse
|
24
|
An extra X does not prevent acquired hemophilia – Pregnancy-associated acquired hemophilia A. Thromb Res 2017; 151 Suppl 1:S82-S85. [DOI: 10.1016/s0049-3848(17)30074-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
25
|
Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate). Blood Coagul Fibrinolysis 2017; 27:551-6. [PMID: 26829366 PMCID: PMC4935538 DOI: 10.1097/mbc.0000000000000525] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
This prospective, Post-Authorization Safety Surveillance (PASS) study was carried out in patients with hemophilia A or B and inhibitors treated with FEIBA for 1 year to collect real-world data on safety and effectiveness of FEIBA. The study followed a cohort design and did not make stipulations on treatment or observation schedule, as it was designed to observe routine medical practices based on physicians’ treatment decisions, including whether patients received on-demand or prophylaxis with FEIBA. The attending physician maintained documentation, including medical records, laboratory reports, adverse event reports, and so on and a subject diary was used. Eighty-one patients were treated with FEIBA at 40 sites in 10 countries over a 4-year period. Sixty-nine patients (85.2%) had hemophilia A, two had (2.5%) hemophilia B, and ten (12.3%) had acquired hemophilia A. At baseline 45 patients (55.6%) were prescribed prophylaxis and 36 (44.6%) on-demand treatment. This study was novel in following safety and effectiveness in ‘real world’ on-demand and prophylactic use of FEIBA, and was able to collect data in these rare patients under routine clinical practice.
Collapse
|
26
|
|
27
|
Punzalan RC, Gottschall JL. Use and Future Investigations of Recombinant and Plasma-Derived Coagulation and Anticoagulant Products in the Neonate. Transfus Med Rev 2016; 30:189-96. [PMID: 27576087 DOI: 10.1016/j.tmrv.2016.07.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2016] [Accepted: 07/18/2016] [Indexed: 12/27/2022]
Abstract
Although congenital bleeding disorders can manifest in the newborn period, the most common causes of bleeding and thrombosis in neonates are acquired conditions. Factor concentrates are used for specific diagnoses (hemophilia with inhibitors, specific factor deficiency, von Willebrand disease) and approved indications, and increasingly for off-label indications (bleeding in surgery cardiopulmonary bypass, extracorporeal membrane oxygenation). We will review the approved indications for factor products in the neonate and discuss the evidence and rationale for off-label use of factor products in management of bleeding and thrombosis in the neonate.
Collapse
Affiliation(s)
- Rowena C Punzalan
- BloodCenter of Wisconsin, Milwaukee, WI; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
| | - Jerome L Gottschall
- BloodCenter of Wisconsin, Milwaukee, WI; Department of Pathology, Medical College of Wisconsin, Milwaukee, WI
| |
Collapse
|
28
|
Zanon E, Milan M, Gamba G, Ambaglio C, Saggiorato G, Spiezia L, Montani N, Prandoni P. Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study. Thromb Res 2015; 136:1299-302. [PMID: 26505666 DOI: 10.1016/j.thromres.2015.10.032] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2015] [Revised: 09/23/2015] [Accepted: 10/18/2015] [Indexed: 10/22/2022]
Abstract
Despite anti-haemorrhagic therapy with proper doses of activated prothrombin complex concentrate (aPCC, Feiba®), patients with acquired haemophilia A (AHA) have a considerable risk of recurrent bleeding complications. Evidence in support of the benefit-to-risk ratio of prevention strategies with the use of lower doses of aPCC following the end of the initial treatment period is scarce and inconclusive. We report our experience in the management of 18 consecutive patients with AHA admitted to two Haemophilia centres in Italy. We managed the first 11 according to current guidelines (e.g., with conventional aPCC doses until bleeding resolution). Then, we decided to prolong the treatment beyond bleeding resolution with lower doses of the same concentrate (short-term prophylaxis) in the 7 additional patients. In these patients, the treatment was continued for as long as the titre of FVIII inhibitor was found to decrease by at least 50% when compared to the baseline one. We observed six relapses of bleeding in patients in whom aPCC was confined to the treatment of the qualifying bleeding episode, and none in patients to whom lower doses were administered until the pre-specified decrease in the titre of FVIII inhibitor was achieved. No patients experienced thrombotic complications during the study period. Prolonging the treatment with lower doses of aPCC beyond the initial phase in patients with AHA in whom the titre of FVIII inhibitor is still high is likely to safely prevent further bleeding complications.
Collapse
Affiliation(s)
- Ezio Zanon
- Department of Cardiac Thoracic and Vascular Sciences, Haemophilia Centre Unit of Coagulopathies, University Hospital of Padua, Italy.
| | - Marta Milan
- Department of Cardiac Thoracic and Vascular Sciences, Haemophilia Centre Unit of Coagulopathies, University Hospital of Padua, Italy
| | - Gabriella Gamba
- Department of Internal Medicine and Medical Therapy, Diseases of Haemostasis, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
| | - Chiara Ambaglio
- Department of Internal Medicine and Medical Therapy, Diseases of Haemostasis, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
| | | | - Luca Spiezia
- Department of Internal Medicine, University Hospital of Padua, Italy
| | - Nadia Montani
- Department of Internal Medicine and Medical Therapy, Diseases of Haemostasis, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
| | - Paolo Prandoni
- Department of Cardiac Thoracic and Vascular Sciences, Haemophilia Centre Unit of Coagulopathies, University Hospital of Padua, Italy
| |
Collapse
|